Results 251 to 260 of about 11,841,496 (406)

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The clinical spectrum of SMA‐PME and in vitro normalization of its cellular ceramide profile

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1941-1952, December 2022., 2022
Abstract Objective The objectives of this study were to define the clinical and biochemical spectrum of spinal muscular atrophy with progressive myoclonic epilepsy (SMA‐PME) and to determine if aberrant cellular ceramide accumulation could be normalized by enzyme replacement.
Michelle M. Lee, Graeme S. V. McDowell, Darryl C. De Vivo, Daniel Friedman, Samuel F. Berkovic, Maria Spanou, Argirios Dinopoulos, Katheryn Grand, Pedro A. Sanchez‐Lara, Michelle Allen‐Sharpley, Jodi Warman‐Chardon, Alexander Solyom, Thierry Levade, Edward H. Schuchman, Steffany A. L. Bennett, David A. Dyment, Toni S. Pearson   +16 more
wiley   +1 more source

Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine. [PDF]

J Biol Chem
Hernandez G, Osinski A, Majumdar A, Eitson JL, Antczak M, Pawłowski K, Niederstrasser H, Servage KA, Posner B, Schoggins JW, Ready JM, Tagliabracci VS.   +11 more
europepmc   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

CO Cryo-Sorption as a Surface-Sensitive Spectroscopic Probe of the Active Site Density of Single-Atom Catalysts. [PDF]

Angew Chem Int Ed Engl
Jeong B, Abbas HG, Klein BP, Bae G, Velmurugan AR, Choi CH, Kim G, Kim D, Kim KJ, Cha BJ, Kim YD, Jaouen F, Maurer RJ, Ringe S.   +13 more
europepmc   +1 more source

The Alkylation of the Active Site of Trypsin with Iodoacetamide in the Presence of Alkylguanidines

, 1965
Tadashi Inagami
openalex   +1 more source

Detergents: Active Sites in the Wash [PDF]

, 1968

openalex   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Tracking Active Site Formation during Oxidative Activation of Copper-Exchanged Zeolites for Methane-to-Methanol Conversion. [PDF]

Adv Sci (Weinh)
Brenig A, Fischer JWA, Klose D, Jeschke G, van Bokhoven JA, Sushkevich VL.   +5 more
europepmc   +1 more source

Enzymes: Rigid Substrates map Active Site [PDF]

, 1969

openalex   +1 more source